Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + Anlotinib in 2nd-line ES-SCLC
NCT04967625Phase 2Unknown
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jul 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules, Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of sintilimab and anlotinib in small cell lung cancer (SCLC), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Objective Response Rate at 12 months. Status: unknown.
02
Drugs
sintilimabanlotinib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04967625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04967625.